Tuesday April 18, 2006
|
|
Sponsored by:
|
|
|
|
8:00 am
|
|
|
9:15 am
|
|
10:15 am -
11:00 am
|
- There has been an evolution in the involvement of patients in their own healthcare decisions due to increased information, involvement, and decision making, which has led to a high level of consumerism in healthcare
- What effects does this have on the treatment of chronic conditions and can it have a significant impact in treatment outcomes?
- What are some of the tools and strategies that can advance this?
- What are some strategies in cost containment that can actually have a negative impact?
|
| |
Paulo Costa
President and CEO
Novartis Pharmaceuticals Corporation
|
|
|
|
11:15 am -
12:00 pm
|
- Framing a dialogue to define pharmaceutical value for various market segments – consumers, health plans (private and public), physicians and policy makers
- How stakeholders perceive value and implications for their business as the marketplace becomes more discerning around benefits vs. costs
- Exploring the balance between encouraging innovation and moderating pharmaceutical expenses
- Recasting the perception of pharmaceutical value for health care industry sectors
- Strategies to demonstrate value to consumers, providers, payers and public purchasers
|
|
|
|
12:00 pm -
1:30 pm
|
|
1:30 pm -
2:15 pm
|
- Regulatory Risk/Benefit Analysis - Making the judgment call for the public interest
- Results to date from pharmacovigilence efforts for pharma, provider and payors to track adverse drug reactions earlier
|
|
|
|
2:15 pm -
3:30 pm
|
|
2:30 pm -
3:30 pm
|
|
3:30 pm -
4:15 pm
|
|
4:30 pm -
5:15 pm
|
|
5:30 pm -
7:00 pm
|
|
7:00 pm -
9:00 pm
|
|
Wednesday April 19, 2006
|
7:00 am -
7:45 am
|
|
8:00 am -
8:45 am
|
|
9:00 am -
10:45 am
|
|
11:00 am -
11:45 am
|
- Aligning incentives for patients, physicians, provider organizations and payers to invest in prevention
- Prevention and wellness innovations to improve population health
|
| |
Pat Kelly
President
Pfizer US Pharmaceuticals
 View Biography
|
|
|
|
12:00 pm -
12:45 pm
|
- How large integrated data sets that are now available for analysis can help to create a more efficient health experience for all stakeholders
- Realizing increased efficiencies in clinical research (e.g. trial feasibility, protocol development, etc.)
- Utilizing health data sets in formulary decision making
- Going to market with greater confidence and visibility and mitigating in-market surprises
|
|
|
|
12:45 pm -
2:15 pm
|
|
2:30 pm -
3:30 pm
|
|
3:10 pm -
3:40 pm
|
|
3:45 pm -
4:30 pm
|
|
|
Printer Friendly
Email A Colleague
Bookmark Page
